CollPlant Biotechnologies (NASDAQ:CLGN) Earns Buy Rating from D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $14.00 price objective on the stock. D. Boral Capital’s price target points to a potential upside of 273.33% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Stock Performance

Shares of CLGN stock opened at $3.75 on Tuesday. CollPlant Biotechnologies has a fifty-two week low of $3.24 and a fifty-two week high of $6.75. The stock’s fifty day moving average price is $3.90 and its two-hundred day moving average price is $4.33. The company has a market cap of $42.94 million, a PE ratio of -2.44 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its quarterly earnings data on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same period last year, the business earned ($0.38) earnings per share. On average, equities analysts predict that CollPlant Biotechnologies will post -1.44 EPS for the current fiscal year.

Institutional Trading of CollPlant Biotechnologies

Hedge funds have recently made changes to their positions in the company. AMH Equity Ltd raised its holdings in CollPlant Biotechnologies by 17.4% in the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after buying an additional 17,295 shares during the last quarter. Benjamin Edwards Inc. acquired a new position in CollPlant Biotechnologies in the 3rd quarter valued at approximately $112,000. Finally, Villere ST Denis J & Co. LLC raised its stake in shares of CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after acquiring an additional 95,000 shares during the last quarter. 21.69% of the stock is owned by institutional investors and hedge funds.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.